Psoriasis News and Research RSS Feed - Psoriasis News and Research

Psoriasis is a chronic, immune-mediated disease that results from the overproduction of skin cells, resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that approximately 7.5 million Americans and nearly 3 percent of the world's population are living with psoriasis and nearly one-quarter of those people have cases that are considered moderate to severe.
New report reveals prescription medication costs may increase up to 13% in 2016

New report reveals prescription medication costs may increase up to 13% in 2016

Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures. [More]
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met. [More]
Study demonstrates role of leukocyte activation receptor CD69 in development of psoriasis

Study demonstrates role of leukocyte activation receptor CD69 in development of psoriasis

Scientists at the Centro de Investigaciones Cardiovasculares Carlos III have defined the key role of an immune-system receptor in the development of psoriasis, suggesting that it could serve as a therapeutic target for the control of this disease. [More]
Global survey reveals 84% of psoriasis patients suffer discrimination, humiliation

Global survey reveals 84% of psoriasis patients suffer discrimination, humiliation

Novartis today released new results from the largest global survey to date of people with psoriasis. [More]
New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a newly developed method of evaluating the impact of different comorbidities in patients with Psoriatic Arthritis (PsA) can be used to prospectively identify those PsA patients at greater risk of hospitalisation and premature death. [More]
New drug ixekizumab helps clear severe psoriasis symptoms

New drug ixekizumab helps clear severe psoriasis symptoms

About 80 percent of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab, according to three large, long-term clinical trials led by Northwestern Medicine. [More]
B lymphocytes can influence psoriasis by regulating cytokine IL-10

B lymphocytes can influence psoriasis by regulating cytokine IL-10

"A pathological and very complex autoimmune reaction of the skin": This is the definition doctors and scientists use to describe psoriasis, a disease that affects one to three percent of the population. [More]
Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

Autoimmune diseases among lung cancer patients may make them unsuitable for immunotherapy

A significant proportion of lung cancer patients also have autoimmune disease, which may make them unsuitable for increasingly popular immunotherapy treatments, a team of researchers at UT Southwestern Medical Center's Harold C. Simmons Comprehensive Cancer Center has found. [More]
Review sheds new light on link between smoking habits and psoriasis

Review sheds new light on link between smoking habits and psoriasis

Psoriasis: Targets and Therapy has published the review "Psoriasis and smoking: links and risks". As corresponding author Professor Luigi Naldi says "The review in Psoriasis: Targets and Therapy throws new light on the relation between smoking habits and psoriasis. [More]
SBP scientists discover new regulator of immune responses

SBP scientists discover new regulator of immune responses

Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors. [More]
Japanese scientists find evidence that cytokine IL-17A plays crucial role in psoriasis

Japanese scientists find evidence that cytokine IL-17A plays crucial role in psoriasis

Psoriasis is an inflammatory skin condition that affects some 125 million people worldwide. It is characterized by itchy, scaly skin plaques. The exact cause of psoriasis is unclear. [More]
Researchers find genetic mutations linked to increased risk factor for PTSD

Researchers find genetic mutations linked to increased risk factor for PTSD

In the largest study of DNA samples from service members with Post-Traumatic Stress Disorder (PTSD), researchers have identified genetic mutations that may be associated with an increased risk factor for PTSD. [More]
Penn State researchers link mutation in common virus to fatal brain disease

Penn State researchers link mutation in common virus to fatal brain disease

Why people on immunosuppressant drugs for autoimmune conditions have a higher incidence of an often-fatal brain disease may be linked to a mutation in a common virus, according to researchers at Penn State College of Medicine. [More]
Two statistically significant genetic variants may be linked to increased PTSD risk in veterans

Two statistically significant genetic variants may be linked to increased PTSD risk in veterans

In a massive analysis of DNA samples from more than 13,000 U.S. soldiers, scientists have identified two statistically significant genetic variants that may be associated with an increased risk of post-traumatic stress disorder (PTSD), an often serious mental illness linked to earlier exposure to a traumatic event, such as combat and an act of violence. [More]
People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

In a new University of Manchester study, people with psoriatic arthritis have told researchers about the condition's deeply damaging mental effects and how healthcare services failed to prepare them for its reality. [More]
Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Lilly's ixekizumab (Taltz) granted EC marketing authorisation for treatment of plaque psoriasis

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation for ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union (EU) who are candidates for systemic therapy. [More]
New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
MALT1 inhibitors may be useful for treating psoriasis patients with CARD14 mutations

MALT1 inhibitors may be useful for treating psoriasis patients with CARD14 mutations

Psoriasis is a long-lasting autoimmune disease that is characterized by patches of abnormal and inflamed skin. It is generally thought to have a genetic origin, which can be further triggered by environmental factors. People with specific mutations in the CARD14 gene have a high probability of developing psoriasis. [More]
Taking antibiotics in early childhood can disrupt immune system function lifelong

Taking antibiotics in early childhood can disrupt immune system function lifelong

Scientists want to know whether taking antibiotics early in life can disrupt your immune system function lifelong. [More]
Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. [More]
Advertisement